ciglitazone has been researched along with Vasculitis in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verrier, E | 1 |
| Wang, L | 1 |
| Wadham, C | 1 |
| Albanese, N | 1 |
| Hahn, C | 1 |
| Gamble, JR | 1 |
| Chatterjee, VK | 1 |
| Vadas, MA | 1 |
| Xia, P | 1 |
1 other study available for ciglitazone and Vasculitis
| Article | Year |
|---|---|
PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.
Topics: Animals; Aorta; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Chromans; Diabetic | 2004 |